Weekly Recap | TRANSTHERA-B -5.78%, late-week drop below HK$8Weekly Review·Nov 14, 2026 at 05:26 AM02617-4.17%
Weekly Recap | TRANSTHERA-B +2.34%, share conversion approval stirs volatilityWeekly Review·Nov 7, 2026 at 05:53 AM02617-4.17%
Transthera drops 6% on approval to convert unlisted shares to H sharesMarket Movers·Nov 2, 2026 at 01:55 AM02617-4.17%
TransThera Wins Approval to Convert 44,971,128 Unlisted Shares Into H SharesPUBT·Nov 1, 2026 at 10:17 AM02617-4.17%
Transthera Sciences Discloses Share Buyback in HKEX Next-Day ReturnPUBT·Oct 27, 2026 at 10:51 AM02617-4.17%
TransThera Sciences Completes CSRC Filing to Convert 44,971,128 Domestic Shares Into H SharesPUBT·Oct 26, 2026 at 02:46 PM02617-4.17%
Transthera Sciences Files Next-Day Disclosure Return With HKEX Announcing Share BuybackPUBT·Oct 26, 2026 at 12:16 PM02617-4.17%
Weekly Recap | TRANSTHERA-B -5.07%, kicking off Yochanra national rolloutWeekly Review·Oct 24, 2026 at 05:24 AM02617-4.17%
TransThera Sciences Files HKEX Next Day Disclosure Return on Share BuybackPUBT·Oct 23, 2026 at 09:01 AM02617-4.17%
TransThera launches national rollout of first-in-China cholangiocarcinoma drug YochanraTip Ranks·Oct 22, 2026 at 04:08 AM02617-4.17%